Results 1 to 10 of about 382,034 (365)

Glioma progression is shaped by genetic evolution and microenvironment interactions

Cell, 2022
Summary The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treatment-associated cellular and genetic changes, we analyzed RNA and/or DNA sequencing data from the temporally separated tumor pairs of 304 adult ...
Peter V Gould, David M Ashley, Christoph Böck   +2 more
exaly   +2 more sources

Vorasidenib in IDH1- or IDH2-mutant Low-Grade Glioma

New England Journal of Medicine, 2023
Background: Isocitrate dehydrogenase (IDH)-mutant grade 2 gliomas are malignant brain tumors causing considerable morbidity and premature death. Vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, showed preliminary activity ...
I. Mellinghoff, M. J. van den Bent, D. Blumenthal, M. Touat, K. Peters, Jennifer L. Clarke, Joe S. Mendez, S. Yust-Katz, L. Welsh, W. Mason, F. Ducray, Y. Umemura, B. Nabors, M. Holdhoff, A. Hottinger, Yoshiki Arakawa, J. Sepúlveda, W. Wick, R. Soffietti, J. Perry, P. Giglio, M. I. de la Fuente, E. Maher, S. Schoenfeld, Dan Zhao, S. Pandya, L. Steelman, Islam Hassan, P. Wen, T. Cloughesy   +29 more
semanticscholar   +1 more source

Anti-glioma effect of ginseng-derived exosomes-like nanoparticles by active blood–brain-barrier penetration and tumor microenvironment modulation

Journal of Nanobiotechnology, 2023
Inhibition of tumor growth and normalization of immune responses in the tumor microenvironment (TME) are critical issues for improving cancer therapy. However, in the treatment of glioma, effective nanomedicine has limited access to the brain because of ...
Ji-Seong Kim, Ying Zhu, Sunhui Chen, Dongdong Wang, Shuya Zhang, Jiaxuan Xia, Shiyi Li, Qiujun Qiu, Hyukjin Lee, Jianxin Wang   +9 more
semanticscholar   +1 more source

Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target

Nature Communications, 2022
A major rate-limiting step in developing more effective immunotherapies for GBM is our inadequate understanding of the cellular complexity and the molecular heterogeneity of immune infiltrates in gliomas. Here, we report an integrated analysis of 201,986
Nourhan Abdelfattah, Parveen Kumar, Caiying Wang, Jia-Shiun Leu, W. Flynn, Ruli Gao, D. Baskin, K. Pichumani, O. Ijare, Stephanie L. Wood, S. Powell, D. Haviland, Brittany C Parker Kerrigan, F. Lang, S. Prabhu, Kristin M. Huntoon, Wen Jiang, Betty Y. S. Kim, J. George, Kyuson Yun   +19 more
semanticscholar   +1 more source

ZDHHC15 promotes glioma malignancy and acts as a novel prognostic biomarker for patients with glioma

BMC Cancer, 2023
Background Glioma is the most common and aggressive tumor in the adult brain. Recent studies have indicated that Zinc finger DHHC-type palmitoyltransferases (ZDHHCs) play vital roles in regulating the progression of glioma.
Zhen-Yuan Liu, Tian Lan, Feng Tang, Yong-Ze He, Jin-Sheng Liu, Jin-Zhou Yang, Xi Chen, Ze-Fen Wang, Zhi-Qiang Li   +8 more
doaj   +1 more source

PTPRZ1-MET FUsion GENe (ZM-FUGEN) trial: study protocol for a multicentric, randomized, open-label phase II/III trial

Chinese Neurosurgical Journal, 2023
Background PTPRZ1-MET fusion was reported to associate with glioma progression from low-grade to high-grade glioma, which was a target by a MET inhibitor vebreltinib.
Zhaoshi Bao, Shouwei Li, Liang Wang, Bisi Zhang, Peilong Zhang, Hepeng Shi, Xiaoguang Qiu, Tao Jiang   +7 more
doaj   +1 more source

Clinical and Biological Significances of a Methyltransferase-Related Signature in Diffuse Glioma

Frontiers in Oncology, 2020
Methylation of DNA, RNA or protein is a reversible modification. The proteins and genes that regulate this modification can be a candidate target for tumor therapy. However, the characteristics of methyltransferase related genes in glioma remain obscure.
Ying Zhang, Ying Zhang, Yuqing Liu, Yuqing Liu, Hanjie Liu, Hanjie Liu, Zheng Zhao, Zheng Zhao, Fan Wu, Fan Wu, Fan Zeng, Fan Zeng   +11 more
doaj   +1 more source

EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3

Molecular Cancer, 2022
Background Gliomas are the most common malignant primary brain tumours with a highly immunosuppressive tumour microenvironment (TME) and poor prognosis.
Z. Pan, Rongrong Zhao, Boyan Li, Yanhua Qi, W. Qiu, Qindong Guo, Shouji Zhang, Shulin Zhao, Hao Xu, Ming Li, Zijie Gao, Yang Fan, Jianye Xu, Huizhi Wang, Shaobo Wang, J. Qiu, Qingtong Wang, Xing Guo, Lin Deng, Ping Zhang, H. Xue, Gang Li   +21 more
semanticscholar   +1 more source

Immunological profiles of human oligodendrogliomas define two distinct molecular subtypesResearch in context

EBioMedicine, 2023
Summary: Background: Human oligodendroglioma presents as a heterogeneous disease, primarily characterized by the isocitrate dehydrogenase (IDH) mutation and 1p/19q co-deletion.
Fan Wu, Yi-Yun Yin, Wen-Hua Fan, You Zhai, Ming-Chen Yu, Di Wang, Chang-Qing Pan, Zheng Zhao, Guan-Zhang Li, Wei Zhang   +9 more
doaj   +1 more source

TERT mutations-associated alterations in clinical characteristics, immune environment and therapy response in glioblastomas

Discover Oncology, 2023
Objective TERT is the most frequently mutated gene in adult glioblastomas (GBMs) defined by the 2021 World Health Organization classification system. The present study aims to explore differences in clinical characteristics and immune microenvironment ...
Feng Tang, Xi Chen, Jin-Sheng Liu, Zhen-Yuan Liu, Jin-Zhou Yang, Ze-Fen Wang, Zhi-Qiang Li   +6 more
doaj   +1 more source